One main reason for recommending the initiation of an insulin‐based anti‐DM regimen in newly diagnosed DM patients with severe hyperglycaemia (glucose > 300 mg/dL or hbA1c > 10%–12%) is the understanding that such patients have insulinopenia and a state of glucose toxicity [29]. The gene discussed is INS; the disease is Hyperglycemia.